Novavax today announced the Food and Drug Administration expanded the emergency use authorization for its Adjuvanted (NVX-CoV2373) COVID-19 vaccine. Under the expanded EUA, the two-dose primary series can be administered for adolescents between the ages of 12 and 17. The vaccine was previously subject to an EUA for adults over the age of 18. FDA’s decision was based on data from Novavax’s ongoing pediatric expansion of its phase 3 clinical trial, which indicated a clinical efficacy of 78.29% in preventing SARS-CoV-2 infections, Novavax said. Novavax notes that its pediatric trial culled data during a period in which the SARS-CoV-2 delta variant was the predominant strain in the U.S. 

Related News Articles

Headline
AHA today participated in a Centers for Disease Control and Prevention Fall Immunization Kick-off Event for partner organizations, which focused on vaccinating…
Headline
AHA is providing its latest social media toolkit to help hospitals encourage vaccination against COVID-19. The newest toolkit includes messages and assets…
Headline
The Food and Drug Administration’s independent Nonprescription Drugs Advisory Committee Sept. 12 by unanimous vote declared oral phenylephrine…
Headline
As authorized yesterday by the Food and Drug Administration and recommended by its vaccine advisory committee, the Centers for Disease Control and Prevention…
Headline
Under the Department of Health and Human Services’ recent agreement with Regeneron to develop a new monoclonal antibody to prevent COVID-19, the U.S. list…
Headline
In time for back-to-school health screenings, AHA Aug. 25 released an infographic on strategies that clinicians and the Centers for Disease Control and…